Genmab — Juni 2019
-
@Vitus - jeg synes du bør afholde dig fra at kritisere netop Bulder og Sukkeralf. Det er de 2 mest velfunderede personer på denne chatside. Og disse 2 er ikke på nogen måde „hypere“, der kommer med ubegrundede bullish påstulater. Det er min konklusion efter at have læst med her de sidste 6 år...
-
Mest viden om emnet. Uden deres medvirken, ville chattens værdi blive reduceret umådeligt meget
-
Her
-
Alle må kritiseres pænt og ordentligt
-
@Vitus, Georgebest har altså ret, der findes ikke bedre end Bulder og Sukkeralf, super dygtige og saglige
-
Hvis kommentarerne kunne holdes til at omhandle emnet og ikke skribenten, så ville vi være langt. Men nogle drømme må jo dø.
-
Det tog 5 måneder for Pembrolizumab. Side 13. https://www.focr.org/sites/default/files/Friends Annual Meeting Panel 3 Slides.pdf
-
jeg tænker, at der ingen grund er til panik. Fda ved jo også, at de har fremtidens SOC mellem hænderne. Så skal t’erne krydses og i’erne dottes til perfektion
-
Lad os da håbe der ikke går 5 mdr for maia. For så lugter begynder det af nedjustering
-
Genmab Announces U.S. FDA Approval of DARZALEX
(daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Company AnnouncementDARZALEX (daratumumab) approved by U.S. FDA in combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant
Approval based on Phase III MAIA study
Copenhagen, Denmark; June 27, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) -
offer their patients the option to add DARZALEX to this regimen in the U.S.,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
The approval was based on data from the Phase III MAIA (MMY3008) study of daratumumab in combination with lenalidomide and dexamethasone as treatment for patients with newly diagnosed multiple myeloma, who are not candidates for high dose chemotherapy and ASCT. Data from this study was presented as a Late-Breaking Abstract at the 2018 American Society o
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind